These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 31626906

  • 1. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
    Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG.
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
    [Abstract] [Full Text] [Related]

  • 2. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E.
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [Abstract] [Full Text] [Related]

  • 3. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M.
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X.
    Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
    [Abstract] [Full Text] [Related]

  • 6. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M.
    Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 8. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L, Newbold P, Wu Y, Trudo F.
    Allergy Asthma Proc; 2018 Sep 04; 39(5):345-349. PubMed ID: 30077185
    [Abstract] [Full Text] [Related]

  • 9. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
    Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG.
    Eur Respir J; 2018 Oct 04; 52(4):. PubMed ID: 30139780
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
    Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R.
    Adv Ther; 2022 May 04; 39(5):2065-2084. PubMed ID: 35287231
    [Abstract] [Full Text] [Related]

  • 12. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul 04; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma.
    Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ.
    Ann Allergy Asthma Immunol; 2020 Aug 04; 125(2):171-176. PubMed ID: 32334141
    [Abstract] [Full Text] [Related]

  • 15. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
    Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, BORA study investigators.
    Lancet Respir Med; 2019 Jan 04; 7(1):46-59. PubMed ID: 30416083
    [Abstract] [Full Text] [Related]

  • 16. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
    Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Brooks L, Olsson RF, Martin UJ, Goldman M, BORA study investigators.
    J Allergy Clin Immunol; 2021 Jul 04; 148(1):266-271.e2. PubMed ID: 33609624
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma.
    Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L.
    Clin Pharmacol Ther; 2019 Aug 04; 106(2):383-390. PubMed ID: 30661249
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.